A large study examining mutations across 21 tumor types from nearly 5000 patient samples identified SF3B1 mutations across multiple cancer types (pan-cancer cohort), indicating that it is a frequent target of dysregulation in cancer progression [23]. Here, SF3B1 is linked to cancer.